
Teva will get US commercialisation rights for Eticovo upon close and infliximab in Q3 2027

The agreement gives Fresenius exclusive option rights for up to 37 potential first-to-market biosimilar candidates

The new site will expand research capabilities across immunology, neuroscience and oncology

The use of Rinvoq in non-segmental vitiligo is under regulatory review by the US FDA

If approved, this would be the first IL-17A inhibitor licensed in Europe for adults with polymyalgia rheumatica

Around 195,000 people globally will be treated for this form of lung cancer in 2026

The agreement for up to ten biosimilar assets represents one of largest ever biosimilar collaborations for the company

Rinvoq is the first and only systemic medication approved in the EU for NSV

The treatment is for cerebral adrenoleukodystrophy, a rare neurodegenerative disease

Asthma affects over 360 million people worldwide, including over 40 million people in Europe

The acquisition includes clinical-stage candidates for atopic dermatitis and asthma

Spanning four dimensions of skin health, the framework introduces 15 terms and definitions